Skip to content
Screener

Dianthus Therapeutics DNTH Personnel And Related Costs — Research And Development Expense

Other product segments

Share Based Compensation Expense
$4.85M—
Other Costs
$1.49M+25.5%
Discovery Expenses
$1.36M+51.4%

Similar metrics at other companies

Tyra Biosciences, Inc. logo
TYRAPersonnel Costs — Research And Development Expense
$11.79M+46.9%
Tango Therapeutics logo
TNGXPersonnel-Related Expenses-RD — Research And Development Expense
$12.93M-6.6%
Rapport Therapeutics, Inc. logo
RAPPResearch And Development Personnel Related Costs Including Stock-Based Compensation — Research And Development Expense
$10.64M+59.6%
Rein Therapeutics Inc. logo
RNTXEmployee Related Expenses — Research And Development Expense
$500K-19.6%
Solid Biosciences Inc. logo
SLDBInternal Research And Development Expense — Research And Development Expense
$9.06M+33.9%
Disc Medicine logo
IRONInternal Research And Development — Research And Development Expense
$11.31M+67.6%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$6.15B+838%
Enterprise value$5.52B+758%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0×0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001690585-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Preclinical study activity costs3201,041
Total claseprubart program-related expenses18,18916,591
Discovery expenses1,363900
Personnel and related costs8,6355,847
Stock-based compensation expense4,8482,475
Other costs1,4931,190
Total research and development expenses34,52827,003
General and administrative expenses:

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dianthus Therapeutics's personnel and related costs — research and development expense?
Dianthus Therapeutics (DNTH) reported personnel and related costs — research and development expense of $8.64M in Q1 2026.
How has Dianthus Therapeutics's personnel and related costs — research and development expense changed year-over-year?
Dianthus Therapeutics's personnel and related costs — research and development expense increased by 47.7% year-over-year, from $5.85M to $8.64M.
What does personnel and related costs — research and development expense mean?
This metric represents the portion of total research and development expenditures specifically allocated to compensation, benefits, and related personnel costs for scientific and clinical staff. It reflects the company's investment in human capital dedicated to advancing its drug pipeline and clinical trial programs. Monitoring this figure helps investors assess the company's commitment to innovation and the intensity of its internal research capabilities.

Ask your AI about Dianthus Therapeutics's personnel and related costs — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude